Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Adolescent Fibromyalgia Study

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Pfizer Identifier:
First received: November 23, 2009
Last updated: October 7, 2014
Last verified: October 2014

This study will compare pregabalin with placebo over a 15 week period in adolescents with fibromyalgia aged 12-17 years to evaluate the safety and efficacy of pregabalin.

Condition Intervention Phase
Drug: placebo
Drug: pregabalin (Lyrica)
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A 15 Week, Randomized, Double Blind, Parallel-group, Placebo-controlled, Flexible-dose, Safety And Efficacy Study Of Pregabalin In Adolescents (12-17 Years Old) With Fibromyalgia

Resource links provided by NLM:

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • change from baseline to week 15 in mean pain diary score [ Time Frame: 15 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • change from baseline to week 15 in mean sleep quality diary score [ Time Frame: 15 weeks ] [ Designated as safety issue: No ]
  • Pain Numeric Rating Scale (Pain-NRS) [ Time Frame: 15 weeks ] [ Designated as safety issue: No ]
  • Patient Global Impression of Change [ Time Frame: 15 weeks ] [ Designated as safety issue: No ]
  • weekly change from baseline in mean pain score at weeks 1-15 [ Time Frame: weeks 1-15 ] [ Designated as safety issue: No ]
  • weekly change from baseline in mean sleep quality score at week 1-15 [ Time Frame: weeks 1-15 ] [ Designated as safety issue: No ]

Estimated Enrollment: 106
Study Start Date: May 2010
Estimated Study Completion Date: December 2014
Estimated Primary Completion Date: October 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo Drug: placebo
matching placebo capsules twice daily.
Experimental: drug-pregabalin Drug: pregabalin (Lyrica)
75-450mg/day pregabalin dose optimised at start of study
Other Name: pregabalin (Lyrica)


Ages Eligible for Study:   12 Years to 17 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of fibromyalgia
  • 12-17 years of age

Exclusion Criteria:

  • Patients with other pain conditions
  • Previous treatment with pregabalin
  • Patients taking excluded medication
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01020474

  Hide Study Locations
United States, California
Childrens Hospital Los Angeles
Los Angeles, California, United States, 90027
Apex Research Institute
Santa Ana, California, United States, 92705
United States, Florida
Florida Medical Center & Research, Inc
Coral Gables, Florida, United States, 33134
Eileen Messing, Psy D.
Delray Beach, Florida, United States, 33446
Delray Research Associates
Delray Beach, Florida, United States, 33484
Arthritis Associates of South Florida
Delray Beach, Florida, United States, 33484
Harmony Clinical Research, Incorporated
North Miami Beach, Florida, United States, 33162
Rheumatology Associates of Central Florida, PA
Orlando, Florida, United States, 32806
United States, Georgia
Medical Research & Health Education Foundation, Inc.
Columbus, Georgia, United States, 31909
North Georgia Rheumatology, PC
Lawrenceville, Georgia, United States, 30045
United States, Kentucky
University Pediatric Rheumatology of Kentucky, LLC
Louisville, Kentucky, United States, 40202
Kosair Children's Hospital
Louisville, Kentucky, United States, 40202
University of Louisville
Louisville, Kentucky, United States, 40202
Kosair Charities Pediatric Clinical Research Unit
Louisville, Kentucky, United States, 40202
United States, Massachusetts
University of Massachusetts Memorial Medical Center Department of Pediatrics
Worcester, Massachusetts, United States, 01655
United States, Missouri
A&A Pain Institute of St. Louis
St. Louis, Missouri, United States, 63141
United States, North Carolina
Duke University Medical Center
Durham, North Carolina, United States, 27717
Duke Medicine Plaza
Raleigh, North Carolina, United States, 27609
United States, Ohio
Akron Children's Hospital
Akron, Ohio, United States, 44308
Akron Children's Hospital
Boardman, Ohio, United States, 44512
Boardman Medical Pavilion
Boardman, Ohio, United States, 44512
University of Cincinnati
Cincinnati, Ohio, United States, 45219
Nationwide Children's Hospital
Columbus, Ohio, United States, 43205
The Research Institute at Nationwide Children's Hospital
Columbus, Ohio, United States, 43205
United States, Pennsylvania
St. Christopher's Hospital for Children / Section of Rheumatology
Philadelphia, Pennsylvania, United States, 19134-1095
United States, South Carolina
Medical University of South Carolina
Charleston, South Carolina, United States, 29425
Medical University of South Carolina, Pediatric Rheumatology
Charleston, South Carolina, United States, 29425
MUSC University Children's Hospital
Charleston, South Carolina, United States, 29425
Carolina Research Center
Myrtle Beach, South Carolina, United States, 29572
United States, Utah
Fatigue Consultation Clinic
Salt Lake City, Utah, United States, 84102
Czech Republic
Bioregeneracni a rehabilitacni centrum
Ricany, Czech Republic, 25101
Krishna Institute of Medical Sciences Ltd
Secunderabad, Andhra Pradesh, India, 500 003
Mallikatta Neuro Centre
Mangalore, Karnataka, India, 575002
Sushrut Hospital, Research Centre & Post Graduate Institute of Orthopaedics
Nagpur, Maharashtra, India, 440010
Department of Physical Medicine & Rehabilitation
Lucknow, Uttar Pradesh, India, 226 018
National Taiwan University Hospital
Taipei, Taiwan, 100
Sponsors and Collaborators
Study Director: Pfizer Call Center Pfizer
  More Information

Additional Information:
No publications provided

Responsible Party: Pfizer Identifier: NCT01020474     History of Changes
Other Study ID Numbers: A0081180, 2010-019521-34
Study First Received: November 23, 2009
Last Updated: October 7, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Pfizer:
juvenile primary fibromyalgia syndrome
pediatric fibromyalgia
and Lyrica

Additional relevant MeSH terms:
Myofascial Pain Syndromes
Muscular Diseases
Musculoskeletal Diseases
Nervous System Diseases
Neuromuscular Diseases
Rheumatic Diseases
Calcium Channel Blockers
Cardiovascular Agents
Central Nervous System Agents
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses processed this record on November 20, 2014